Medtronic, Inc. (NYSE: MDT) today announced it received Health Canada approval for the Medtronic Ablation Frontiers Cardiac Ablation System, a novel radiofrequency (RF) ablation technology for the treatment of atrial fibrillation (AF). AF is the most common heart arrhythmia that affects more than 250,000 Canadians and seven million people worldwide.
“As one of the newest tools in Medtronic's rapidly growing AF Solutions portfolio, our aim is to provide physicians with easy-to-use ablation technologies that help them safely treat those suffering from AF, when used as indicated”
The Medtronic Ablation Frontiers Cardiac Ablation System tools now approved for use in Canada include the GENius™ Multi-Channel Radiofrequency Generator and the Pulmonary Vein Ablation Catheter (PVAC)™, a single anatomically shaped mapping and ablation catheter designed to efficiently isolate the pulmonary veins to treat AF. The GENius generator and PVAC, with the addition of the Multi-Array Septal Catheter (MASC)™ and Multi-Array Ablation Catheter (MAAC)™, are available in Europe and are under investigational use in the United States. Medtronic will provide periodic clinical updates on the safety and effectiveness of the PVAC catheter as a condition of Health Canada's approval.
"This three-dimensional RF catheter is an improvement from the currently used focal system; it simplifies the AF ablation procedure allowing me to better predict my procedure times and therefore, treat more patients in one day," said Yaariv Khaykin, M.D., electrophysiologist at the Southlake Regional Health Centre in Newmarket, Ontario, who was the first to use the new technology in Canada. "This novel technology also gives me the flexibility to tailor ablation therapy for specific patient needs and different anatomies."